Zosano Pharma Corporation

(NASDAQ:ZSAN)

Latest On Zosano Pharma Corporation (ZSAN):

Date/Time Type Description Signal Details
2022-06-02 17:15 ESTNewsZosano Pharma files for Chapter 11 bankruptcy protection; shares plummet 46%N/A
2022-05-14 05:54 ESTNewsZosano Pharma  GAAP EPS of -$7.86 misses by $7.81, revenue of $0.14M beats by $0.04MN/A
2022-04-30 09:25 ESTNewsZosano Pharma suspends program for migraine treatment M207N/A
2022-04-12 19:36 ESTNewsZosano Pharma slips as reverse stock split takes effectN/A
2022-04-11 13:01 ESTNewsZosano Pharma's Board approves 1-for-35 reverse stock splitN/A
2022-03-18 03:43 ESTNewsZosano Pharma  GAAP EPS of -$0.06 misses by $0.02, revenue of $0.09M misses by $1.39MN/A
2022-02-09 21:53 ESTNewsZosano Pharma plunges 48% on pricing $15.4M common stock and warrants offeringN/A
2022-02-09 03:16 ESTNewsZosano Pharma commences public offeringN/A
2021-11-18 04:45 ESTNewsZosano formulates COVID-19 vaccine candidate using patch technologyN/A
2021-11-10 19:02 ESTNewsZosano Pharma  EPS beats by $0.01, beats on revenueN/A
2021-10-04 16:52 ESTNewsZosano granted Type C FDA meeting for Qtrypta NDA resubmission for migraineN/A
2021-09-22 11:43 ESTNewsWarning: ZSAN has been downgraded to Very Bearish.N/A
2021-08-11 11:24 ESTNewsZosano Pharma  EPS beats by $0.02, beats on revenueN/A
2021-07-22 10:32 ESTNewsData supports long-term benefit of Zosano's migraine candidate; shares surge 23%N/A
2021-07-22 09:42 ESTNewsZosano Pharma granted patent related to migraine treatment M207N/A
2021-04-30 22:12 ESTNewsZosano Pharma: Early PK+Safety Study In Q3 2021 May Breathe New Life Into This BiotechN/A
2021-04-26 10:09 ESTNewsZosano shares rise on migraine treatment NDA resubmission updateN/A
2021-03-16 22:29 ESTAnalyst RatingThe Analyst Target Price has increased from $1.83 to $2.17.Buy
2021-03-12 08:52 ESTFinancialsCompany financials have been released.Neutral
2021-03-12 05:03 ESTEarnings EstimateAn EPS average of -$0.33 is estimated for the 2022 year.Sell
2021-03-12 05:03 ESTEarnings EstimateAn EPS average of -$0.10 is estimated for the quarter ending on June 30, 2021.Sell
2021-03-11 17:29 ESTNewsZosano Pharma EPS beats by $0.01N/A
2021-02-22 12:00 ESTNewsZosano Pharma confirms NDA resubmission strategy for QtryptaN/A
2021-02-10 21:49 ESTNewsTLRY, GLUU, ABEO and TYME among premarket gainersN/A
2021-02-01 23:17 ESTNewsZosano Pharma up 21% following FDA feedback on Qtrypta application; presents Qtrypta data in migraineN/A
2021-01-04 17:04 ESTNewsZosano Pharma requests FDA meeting for its Qtrypta applicationN/A
2020-11-26 22:12 ESTFinancialsCompany financials have been released.Neutral
2020-11-26 13:58 ESTAnalyst RatingThe Analyst Target Price has decreased from $2 to $1.83.Neutral
2020-11-19 06:02 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 05:47 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 05:47 ESTEarnings EstimateAn EPS average of -$0.10 is estimated for the quarter ending on March 31, 2021.Buy
2020-11-14 15:22 ESTNewsZosano Pharma EPS misses by $0.01N/A
2020-11-08 01:23 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 17:39 ESTFinancialsCompany financials have been released.Neutral
2020-10-30 15:21 ESTAnalyst RatingThe Analyst Target Price has decreased from $3.83 to $2.Neutral
2020-10-22 09:24 ESTNewsFDA rejects Zosano Pharma application for QtrytpaN/A
2020-10-17 08:46 ESTNewsStocks To Watch: GM's Hummer Charges The EV Party, Earnings BlitzN/A
2020-10-05 14:23 ESTAnalyst RatingThe Analyst Target Price has decreased from $4.33 to $3.83.Neutral
2020-10-02 04:38 ESTNewsZosano plunges after FDA discipline review letter for Qtrypta; approval not expected by October 20N/A
2020-09-26 14:39 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 06:44 ESTFinancialsCompany financials have been released.Neutral
2020-09-02 00:18 ESTNewsZosano Pharma prices public offering; shares under pressureN/A
2020-08-31 18:57 ESTNewsZosano Pharma under pressure on planned equity offeringN/A
2020-08-18 23:27 ESTNewsZosano Pharma teams up with Mitsubishi Tanabe Pharma on patch-administered drugN/A
2020-08-14 10:39 ESTFinancialsCompany financials have been released.Neutral
2020-08-13 04:19 ESTNewsZosano Pharma partners with Eversana Life Science, announces $5M revolving credit facilityN/A
2020-08-08 02:08 ESTFinancialsCompany financials have been released.Neutral
2020-08-07 05:53 ESTNewsZosano Pharma  EPS in-lineN/A
2020-08-06 10:00 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 18:24 ESTFinancialsCompany financials have been released.Neutral

About Zosano Pharma Corporation (ZSAN):

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.

ZSAN Quotes by TradingView

See Advanced Chart

General

  • Name Zosano Pharma Corporation
  • Symbol ZSAN
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 45
  • Last Split Factor1:20
  • Last Split Date2018-01-26
  • Fiscal Year EndDecember
  • IPO Date2015-01-27
  • Gic SectorHealth Care
  • Gic GroupHealth Care Equipment & Services
  • Gic IndustryHealth Care Equipment & Supplies
  • Gic SubIndustryHealth Care Equipment
  • Web URLhttp://www.zosanopharma.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 2.33
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.32
  • Next Year EPS Estimate -$0.23
  • Next Quarter EPS Estimate -$0.10
  • Operating Margin -14624%
  • Return on Assets -37%
  • Return on Equity -117%
  • Revenue 224000
  • Earnings Per Share -$2.81
  • Revenue Per Share $0
  • Gross Profit -21569000
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 151.36 million
  • EBITDA -36154000
  • Analyst Target Price $2.17
  • Book Value Per Share $0.47
View More

Share Statistics

  • Shares Outstanding 106.29 million
  • Shares Float 106.16 million
  • % Held by Insiders 36%
  • % Held by Institutions 15.59%
  • Shares Short 8.41 million
  • Shares Short Prior Month 8.94 million
  • Short Ratio 0.5
  • Short % of Float 8%
  • Short % of Shares Outstanding 8%
View More

Technicals

  • Beta 3.85
  • 52 Week High $1.96
  • 52 Week Low $0.33
  • 50 Day Moving Average 1.31
  • 200 Day Moving Average 0.96
View More

Dividends

  • Dividend Date 2018-01-26
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Zosano Pharma Corporation (ZSAN) Dividend Calendar:

ZSAN's last dividend payment was made to shareholders on January 26, 2018.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Zosano Pharma Corporation (ZSAN) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-11$224000-$0.08-$0.0911.11%
2020-09-302020-11-13$N/A-$0.11-$0.10-13.75%
2020-06-302020-08-06$N/A-$0.14-$0.140%
2020-03-312020-05-14$N/A-$0.24-$0.255.25%
2019-12-312020-03-13$N/A-$0.45-$0.485.26%
2019-09-302019-11-14$N/A-$0.55-$0.585.71%
2019-06-302019-08-14$N/A-$0.55-$0.562.36%
2019-03-312019-05-14$N/A-$0.79-$0.78-1.28%
2018-12-312019-03-14$N/A-$0.85-$0.69-23.19%
2018-09-302018-11-14$N/A-$0.68-$0.702.86%
2018-06-302018-08-09$N/A-$0.75-$0.8915.73%
2018-03-312018-04-30$N/A-$4.16-$5.4022.98%
2017-12-312018-03-12$N/A-$3.80-$4.8020.83%
2017-09-302017-11-09$N/A-$4.00-$3.60-11.11%
2017-06-302017-08-10$N/A-$3.40-$3.8010.53%
2017-03-312017-05-09$N/A-$6.80-$6.50-4.62%
2016-12-312017-03-01$N/A-$8.60-$9.004.44%
2016-09-302016-11-09$N/A-$10.40-$10.803.7%
2016-06-302016-08-10$N/A-$10.80-$10.00-8%
2016-03-312016-05-12$N/A-$13.60-$11.40-19.3%
2015-12-312016-03-29$313000-$12.80-$13.303.76%
2015-09-302015-11-09$-95000-$0.72-$0.61-18.03%
2015-06-302015-08-12$95000-$0.63-$0.53-18.87%
2015-03-312015-05-11$218000-$0.47-$0.5311.32%
2014-12-312015-01-27$380000-$1.10-$0.63-74.6%

Zosano Pharma Corporation (ZSAN) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development 16.38 million N/A N/A 5.51 million 25.39 million
Income Before Tax -8.1 million N/A N/A -8.69 million -8.94 million
Selling General Administrative 8.8 million N/A N/A 3.08 million 3.1 million
Gross Profit 53000 N/A N/A N/A 19.74 million
Ebit -7.94 million N/A N/A -8.31 million -8.75 million
Operating Income -7.94 million N/A N/A -8.6 million -8.75 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue 224000 N/A N/A N/A N/A
Cost of Revenue 171000 N/A N/A N/A -19.74 million
Total Other Income Expense Net N/A N/A N/A 103000 -194000
Net Income From Continuing Operations -8.1 million N/A N/A -8.69 million -8.94 million
Net Income Applicable to Common Shares -8.1 million -8.69 million -7.9 million N/A -8.94 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments -3 million N/A -1.38 million N/A 3.5 million
Change to Liabilities N/A -863000 N/A 678000 451000
Total Cash Flow from Investing Activities N/A -3.32 million N/A -821000 -1.23 million
Net Borrowings N/A 1.24 million N/A 580000 1.42 million
Total Cash Flow from Financial Activities 45 million N/A 22.07 million 8.11 million 2.2 million
Change to Operating Activities N/A -248000 N/A -81000 -351000
Change in Cash 33.01 million N/A 12.24 million -176000 -7.76 million
Total Cash from Operating Activities -8.99 million -8 million -8.44 million -7.47 million -8.74 million
Depreciation 476000 N/A 172000 387000 377000
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A N/A N/A N/A N/A
Change to Net Income N/A 425000 N/A 489000 650000
Capital Expenditures 3 million N/A 1.38 million 821000 4.73 million
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities 24.5 million N/A N/A 31.37 million 28.28 million
Total Stockholder Equity 47.52 million N/A N/A 23.97 million 9.39 million
Other Current Liabilities 6.16 million N/A N/A N/A N/A
Total Assets 72.01 million N/A N/A 55.34 million 37.67 million
Common Stock 10000 10000 6000 N/A 2000
Other Current Assets 453000 N/A N/A N/A N/A
Retained Earnings -332.19 million -324.09 million -315.41 million -307.51 million -298.82 million
Other Liabilities N/A 113000 8000 N/A N/A
Other Assets N/A 458000 458000 N/A 458000
Cash 35.26 million N/A N/A 18.56 million 6.32 million
Total Current Liabilities 14.51 million 13.17 million N/A 20.61 million 16.24 million
Other Stockholder Equity N/A N/A N/A N/A N/A
Property, Plant & Equipment 30.91 million 35.83 million 36.01 million N/A 30.4 million
Total Current Assets 35.72 million 44.17 million N/A 19.18 million 6.81 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 47.52 million 55.24 million 18.46 million N/A 9.39 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt 812000 N/A N/A 5.13 million N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 7.55 million 1.97 million N/A 3.26 million 4.36 million

Zosano Pharma Corporation (ZSAN) Chart:

Zosano Pharma Corporation (ZSAN) News:

Below you will find a list of latest news for Zosano Pharma Corporation (ZSAN) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Zosano Pharma Corporation (ZSAN) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Zosano Pharma Corporation (ZSAN) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000158722120000021/0001587221-20-000021-index.htm
2019-02-22UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1587221/000000000019002978/0000000000-19-002978-index.htm
2020-03-30UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1587221/000000000020002732/0000000000-20-002732-index.htm
2019-04-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000089924319010594/0000899243-19-010594-index.htm
2019-12-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000089924319028646/0000899243-19-028646-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1587221/000090266420000945/0000902664-20-000945-index.htm
2020-02-21SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1587221/000091957420001841/0000919574-20-001841-index.htm
2020-03-16SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1587221/000091957420002452/0000919574-20-002452-index.htm
2019-10-15SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1587221/000093583619000548/0000935836-19-000548-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1587221/000093583620000122/0000935836-20-000122-index.htm
2020-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000114036120015090/0001140361-20-015090-index.htm
2020-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000114036120015091/0001140361-20-015091-index.htm
2020-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000114036120015092/0001140361-20-015092-index.htm
2020-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000114036120015093/0001140361-20-015093-index.htm
2020-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000114036120015094/0001140361-20-015094-index.htm
2020-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000114036120015095/0001140361-20-015095-index.htm
2020-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000114036120015096/0001140361-20-015096-index.htm
2020-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000114036120015097/0001140361-20-015097-index.htm
2020-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000114036120015098/0001140361-20-015098-index.htm
2020-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000114036120015099/0001140361-20-015099-index.htm
2018-04-30DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1587221/000119312518143291/0001193125-18-143291-index.htm
2018-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312518164080/0001193125-18-164080-index.htm
2018-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312518164096/0001193125-18-164096-index.htm
2018-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1587221/000119312518164121/0001193125-18-164121-index.htm
2018-05-22DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1587221/000119312518170884/0001193125-18-170884-index.htm
2018-05-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312518170891/0001193125-18-170891-index.htm
2018-06-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312518184460/0001193125-18-184460-index.htm
2018-06-08S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1587221/000119312518188060/0001193125-18-188060-index.htm
2018-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312518190545/0001193125-18-190545-index.htm
2018-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312518239736/0001193125-18-239736-index.htm
2018-08-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312518244320/0001193125-18-244320-index.htm
2018-08-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1587221/000119312518244555/0001193125-18-244555-index.htm
2018-09-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312518281237/0001193125-18-281237-index.htm
2018-09-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312518283218/0001193125-18-283218-index.htm
2018-10-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312518291464/0001193125-18-291464-index.htm
2018-10-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312518299766/0001193125-18-299766-index.htm
2018-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312518326723/0001193125-18-326723-index.htm
2018-11-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1587221/000119312518327257/0001193125-18-327257-index.htm
2018-11-15NT 10-QNotification of inability to timely file Form 10-Q or 10-QSBhttps://www.sec.gov/Archives/edgar/data/1587221/000119312518328025/0001193125-18-328025-index.htm
2019-01-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312519010322/0001193125-19-010322-index.htm
2019-02-14S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1587221/000119312519041104/0001193125-19-041104-index.htm
2019-02-288-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312519057906/0001193125-19-057906-index.htm
2019-03-25CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1587221/000119312519084455/0001193125-19-084455-index.htm
2019-04-08424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1587221/000119312519100738/0001193125-19-100738-index.htm
2019-04-10424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1587221/000119312519102837/0001193125-19-102837-index.htm
2019-04-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312519103960/0001193125-19-103960-index.htm
2019-05-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312519163006/0001193125-19-163006-index.htm
2019-06-04DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1587221/000119312519165066/0001193125-19-165066-index.htm
2019-06-21DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1587221/000119312519178872/0001193125-19-178872-index.htm
2019-07-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312519199005/0001193125-19-199005-index.htm
2019-08-14S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1587221/000119312519221354/0001193125-19-221354-index.htm
2019-08-19424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1587221/000119312519224580/0001193125-19-224580-index.htm
2019-08-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312519224583/0001193125-19-224583-index.htm
2019-10-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312519264141/0001193125-19-264141-index.htm
2019-10-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312519265896/0001193125-19-265896-index.htm
2019-11-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1587221/000119312519302570/0001193125-19-302570-index.htm
2019-11-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312519302646/0001193125-19-302646-index.htm
2019-12-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312519321798/0001193125-19-321798-index.htm
2020-01-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312520003792/0001193125-20-003792-index.htm
2020-02-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312520031413/0001193125-20-031413-index.htm
2020-02-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312520031418/0001193125-20-031418-index.htm
2020-02-11424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1587221/000119312520031509/0001193125-20-031509-index.htm
2020-02-13424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1587221/000119312520035551/0001193125-20-035551-index.htm
2020-02-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312520035589/0001193125-20-035589-index.htm
2020-03-048-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312520061619/0001193125-20-061619-index.htm
2020-03-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312520061815/0001193125-20-061815-index.htm
2020-03-06424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1587221/000119312520063503/0001193125-20-063503-index.htm
2020-03-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312520065237/0001193125-20-065237-index.htm
2020-03-16S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1587221/000119312520073272/0001193125-20-073272-index.htm
2020-03-31CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1587221/000119312520092935/0001193125-20-092935-index.htm
2020-04-14CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1587221/000119312520107390/0001193125-20-107390-index.htm
2020-04-218-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312520113606/0001193125-20-113606-index.htm
2020-05-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312520130961/0001193125-20-130961-index.htm
2020-05-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312520154251/0001193125-20-154251-index.htm
2020-06-08424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1587221/000119312520163683/0001193125-20-163683-index.htm
2020-06-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312520163692/0001193125-20-163692-index.htm
2020-06-11S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1587221/000119312520166675/0001193125-20-166675-index.htm
2020-06-11DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1587221/000119312520166692/0001193125-20-166692-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312520212008/0001193125-20-212008-index.htm
2020-08-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312520216300/0001193125-20-216300-index.htm
2020-08-31424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1587221/000119312520236245/0001193125-20-236245-index.htm
2020-08-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312520236272/0001193125-20-236272-index.htm
2020-09-01424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1587221/000119312520237314/0001193125-20-237314-index.htm
2020-09-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312520239150/0001193125-20-239150-index.htm
2020-09-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312520259949/0001193125-20-259949-index.htm
2020-10-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000119312520273372/0001193125-20-273372-index.htm
2020-03-13SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1587221/000121390020006325/0001213900-20-006325-index.htm
2019-01-04SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1587221/000153561019000026/0001535610-19-000026-index.htm
2020-02-12SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1587221/000153561020000071/0001535610-20-000071-index.htm
2018-07-05SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1587221/000156598118000001/0001565981-18-000001-index.htm
2018-10-163Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000156761918004180/0001567619-18-004180-index.htm
2018-10-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000156761918004186/0001567619-18-004186-index.htm
2019-01-163Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000156761919001254/0001567619-19-001254-index.htm
2019-01-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000156761919001255/0001567619-19-001255-index.htm
2019-02-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000156761919005600/0001567619-19-005600-index.htm
2019-04-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000156761919008954/0001567619-19-008954-index.htm
2019-06-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000156761919013326/0001567619-19-013326-index.htm
2019-06-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000156761919013328/0001567619-19-013328-index.htm
2019-06-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000156761919013330/0001567619-19-013330-index.htm
2019-06-194/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000156761919013711/0001567619-19-013711-index.htm
2019-06-194/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000156761919013713/0001567619-19-013713-index.htm
2019-06-194/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000156761919013715/0001567619-19-013715-index.htm
2019-07-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000156761919014977/0001567619-19-014977-index.htm
2019-07-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000156761919014978/0001567619-19-014978-index.htm
2019-07-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000156761919014979/0001567619-19-014979-index.htm
2019-07-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000156761919014980/0001567619-19-014980-index.htm
2019-07-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000156761919014981/0001567619-19-014981-index.htm
2019-10-233Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000156761919019923/0001567619-19-019923-index.htm
2019-10-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000156761919019924/0001567619-19-019924-index.htm
2020-02-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000156761920001941/0001567619-20-001941-index.htm
2020-05-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000156761920009028/0001567619-20-009028-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000156761920011801/0001567619-20-011801-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000156761920011802/0001567619-20-011802-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000156761920011803/0001567619-20-011803-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000156761920011805/0001567619-20-011805-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000156761920011807/0001567619-20-011807-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000156761920011809/0001567619-20-011809-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000156761920011811/0001567619-20-011811-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000156761920011812/0001567619-20-011812-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000156761920011813/0001567619-20-011813-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000156761920011814/0001567619-20-011814-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000156761920011825/0001567619-20-011825-index.htm
2018-04-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000158722118000013/0001587221-18-000013-index.htm
2018-05-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000158722118000016/0001587221-18-000016-index.htm
2018-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000158722118000018/0001587221-18-000018-index.htm
2018-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000158722118000020/0001587221-18-000020-index.htm
2018-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000158722118000023/0001587221-18-000023-index.htm
2018-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000158722118000025/0001587221-18-000025-index.htm
2018-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000158722118000027/0001587221-18-000027-index.htm
2018-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000158722118000029/0001587221-18-000029-index.htm
2018-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1587221/000158722118000031/0001587221-18-000031-index.htm
2019-03-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000158722119000004/0001587221-19-000004-index.htm
2019-03-2510-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1587221/000158722119000006/0001587221-19-000006-index.htm
2019-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000158722119000011/0001587221-19-000011-index.htm
2019-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1587221/000158722119000013/0001587221-19-000013-index.htm
2019-09-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000158722119000019/0001587221-19-000019-index.htm
2019-10-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000158722119000021/0001587221-19-000021-index.htm
2019-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000158722119000024/0001587221-19-000024-index.htm
2019-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1587221/000158722119000025/0001587221-19-000025-index.htm
2020-03-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000158722120000002/0001587221-20-000002-index.htm
2020-03-1310-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1587221/000158722120000004/0001587221-20-000004-index.htm
2020-03-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000158722120000006/0001587221-20-000006-index.htm
2020-03-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000158722120000008/0001587221-20-000008-index.htm
2020-04-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000158722120000010/0001587221-20-000010-index.htm
2020-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000158722120000013/0001587221-20-000013-index.htm
2020-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1587221/000158722120000014/0001587221-20-000014-index.htm
2020-05-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1587221/000158722120000016/0001587221-20-000016-index.htm
2020-06-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000158722120000019/0001587221-20-000019-index.htm
2020-06-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000158722120000021/0001587221-20-000021-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000158722120000024/0001587221-20-000024-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1587221/000158722120000026/0001587221-20-000026-index.htm
2020-08-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000158722120000029/0001587221-20-000029-index.htm
2019-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000162828019010757/0001628280-19-010757-index.htm
2019-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1587221/000162828019010764/0001628280-19-010764-index.htm
2019-08-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000162828019011173/0001628280-19-011173-index.htm
2019-09-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1587221/000162828019011560/0001628280-19-011560-index.htm
2019-03-27EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1587221/999999999519000534/9999999995-19-000534-index.htm
2020-04-16EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1587221/999999999520000771/9999999995-20-000771-index.htm
2018-12-20CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1587221/999999999718009622/9999999997-18-009622-index.htm
2020-02-05SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1587221/999999999720000509/9999999997-20-000509-index.htm
2020-02-20SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1587221/999999999720000860/9999999997-20-000860-index.htm

Zosano Pharma Corporation (ZSAN) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Zosano Pharma Corporation (ZSAN). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 36%
Institutional Ownership: 1559%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-06-25JOHN PETER WALKERDirectorBuy7,500.00116,511.00https://www.sec.gov/Archives/edgar/data/1587221/000114036120015094/0001140361-20-015094-index.htm
2020-06-25Steven LoChief Executive OfficerBuy146,250.00146,250.00https://www.sec.gov/Archives/edgar/data/1587221/000114036120015097/0001140361-20-015097-index.htm
2020-06-25KENNETH GREATHOUSEDirectorBuy7,500.0017,500.00https://www.sec.gov/Archives/edgar/data/1587221/000114036120015099/0001140361-20-015099-index.htm
2020-06-25Christine MatthewsChief Financial OfficerBuy18,750.0018,750.00https://www.sec.gov/Archives/edgar/data/1587221/000114036120015091/0001140361-20-015091-index.htm
2020-06-25Hayley LewisOfficerBuy18,750.0018,988.00https://www.sec.gov/Archives/edgar/data/1587221/000114036120015093/0001140361-20-015093-index.htm
2020-06-25DONALD J KELLERMANVP, Clinical Dev & Med AffairsBuy18,750.0019,546.00https://www.sec.gov/Archives/edgar/data/1587221/000114036120015092/0001140361-20-015092-index.htm
2019-04-11Aisling Capital IV, LP10% Share HolderBuy428,571.003.501,499,998.502,028,571.00https://www.sec.gov/Archives/edgar/data/1587221/000089924319010594/0000899243-19-010594-index.htm
2019-12-02Aisling Capital IV, LP10% Share HolderBuy689,655.001.45999,999.752,718,226.00https://www.sec.gov/Archives/edgar/data/1587221/000089924319028646/0000899243-19-028646-index.htm
2019-04-11JOHN PETER WALKERPresident & CEOBuy100,000.003.50350,000.00280,228.00https://www.sec.gov/Archives/edgar/data/1587221/000156761919008954/0001567619-19-008954-index.htm
2020-06-25Joseph P HaganDirectorBuy7,500.007,500.00https://www.sec.gov/Archives/edgar/data/1587221/000114036120015095/0001140361-20-015095-index.htm
2020-06-25Linda S GraisDirectorBuy7,500.007,500.00https://www.sec.gov/Archives/edgar/data/1587221/000114036120015098/0001140361-20-015098-index.htm
2020-06-25STEVE ELMSDirectorBuy7,500.007,500.00https://www.sec.gov/Archives/edgar/data/1587221/000114036120015090/0001140361-20-015090-index.htm
2020-06-25KLEANTHIS G XANTHOPOULOSDirectorBuy7,500.008,596.00https://www.sec.gov/Archives/edgar/data/1587221/000114036120015096/0001140361-20-015096-index.htm